Javier Pagonabarraga

Dr. Javier Pagonabarraga

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
ALAbhishek Lenka
Abhishek Lenka
JPJavier Pagonabarraga
Javier Pagonabarraga
PPPramod Kumar Pal
Pramod Kumar Pal
HBHelena Bejr-Kasem
Helena Bejr-Kasem
JKJaime Kulisvesky
Jaime Kulisvesky
OBJECTIVE To explore physicians’ knowledge of and attitudes toward hyperbaric oxygen therapy (HBOT) in order to better understand current diabetic foot ulcer management practices and to determine potential barriers to HBOT use. DESIGN A 24-item questionnaire. SETTING Primary Care Today conference in Toronto, Ont, in May of 2006. PARTICIPANTS Physician attendees, 313 of whom completed the survey. MAIN OUTCOME MEASURES Self-reported knowledge of and attitudes toward HBOT. RESULTS Less than 10% of respondents had a good knowledge of HBOT, but 57% had a good attitude toward HBOT. Knowledge of and attitude toward HBOT were positively correlated (P < .0001). Good knowledge of HBOT was associated with sex (P = .0334), age younger than 40 years (P = .0803), years in medical practice (P = .0646), patient requests for HBOT referrals (P = .0127), and having previously referred patients for HBOT (P < .001). Twenty years or more in medical practice (P = .0593) and receiving patient requests for HBOT (P = .0394) were multivariate predictors of having good knowledge of HBOT. Good attitude toward HBOT was associated with age younger than 40 years (P = .0613) and having previously referred patients for HBOT (P = .0013). Multivariate analysis showed that male physicians (P = .0026) received more patient requests for HBOT (P < .0001), had good knowledge (P = .0129) and a good attitude (P = .0488), and were more likely to refer patients for HBOT. CONCLUSION Primary care physicians have underdeveloped knowledge of HBOT, but their generally positive attitudes toward its use suggest that they might be receptive to educational interventions. Educating both physicians and patients about HBOT, specifically its cost-effectiveness, might encourage future use. RÉSUMÉ OBJECTIF Déterminer ce que les médecins savent et ce qu’ils pensent de l’oxygénothérapie hyperbare (OTHB) afin de mieux comprendre les façons actuelles de traiter l’ulcère du pied diabétique et de déterminer les obstacles potentiels à l’utilisation de l’OTHB. TYPE D’ÉTUDE Un questionnaire de 24 items. CONTEXTE La conférence Primary Care Today à Toronto, en mai 2006 PARTICIPANTS Médecins participants, dont 313 ont complété le questionnaire. PRINCIPAUX PARAMÈTRES À L’ÉTUDE Auto-déclarations concernant leurs connaissances et attitudes envers l’OTHB. RÉSULTATS Moins de 10 % des répondants avaient une bonne connaissance de l’PTHB, mais 57 % avaient une attitude favorable envers ce traitement. Il existait une corrélation positive entre connaissance de l’OTHB et attitude envers ce traitement (P < ,0001). Une bonne connaissance de l’OTHB était associée à des facteurs tels que : sexe (P = ,0334), âge inférieur à 40 ans (P = ,0803), nombre d’années de pratique (P = ,0646), demandes des patients pour avoir ce traitement (P = ,0127) et avoir déjà dirigé des patients en OTHB (P < ,001). Le fait d’avoir 20 ans ou plus de pratique médicale (P = ,0593) et d’avoir eu des demandes d’OTHB de la part de patients (P = ,0394) constituaient des indicateurs multifactoriels d’une bonne connaissance de l’OTHB. Une bonne attitude envers l’OTHB était associée au fait d’avoir moins de 40 ans (P = ,0613) et d’avoir déjà dirigé des patients en OTHB (P = ,0013). L’analyse multifactorielle a révélé que les médecins mâles (P = ,0026) avaient reçu plus de demandes d’OTHB de leurs patients (P < ,0001), avaient une bonne connaissance (P = ,0129) et une attitude positive (P = ,0488) et étaient plus susceptibles de diriger des patients en OTHB. CONCLUSION Les médecins de première ligne ont une connaissance insuffisante de l’OTHB, mais leur attitude généralement positive envers ce traitement suggère qu’ils seraient réceptifs à des interventions formatrices. Instruire médecins et patients sur l’OTHB, notamment sur son rapport coût-bénéfice, pourrait promouvoir son utilisation future.

4 December 2024 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
Carlo CattaneoCarlo Cattaneo
Carlo Cattaneo
JPJavier Pagonabarraga
Javier Pagonabarraga
Sex differences in epidemiology, clinical features, and therapeutical responses are emerging in several movement disorders, even though they are still not widely recognized. Parkinson’s disease (PD) is not an exception: men and women suffering from PD have different levels of disability. Research has been performed using multiple databases and scientific journals; this review summarizes the available evidence on sex differences in PD regarding epidemiology, risk factors, genetics, clinical phenotype, social impact, and therapeutic management. The role of hormones in determining such differences is also briefly discussed. The results confirm the existence of differences between men and women in PD; women have a higher risk of developing disabling motor complications and non-motor fluctuations compared to men, while men have a higher risk of developing cognitive impairment, postural instability, and gait disorders. Improving our knowledge in these differences may result in the implementation of strategies for disease-tailored treatment and management.

10 December 2018 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
HBHelena Bejr‐Kasem
Helena Bejr‐Kasem
JPJavier Pagonabarraga
Javier Pagonabarraga
SMSaül Martínez‐Horta
Saül Martínez‐Horta
FSFrederic Sampedro
Frederic Sampedro
JMJuan Marín‐Lahoz
Juan Marín‐Lahoz
JKJaime Kulisevsky
Jaime Kulisevsky

15 January 2024 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
JPJavier Pagonabarraga
Javier Pagonabarraga
HBHelena Bejr-Kasem
Helena Bejr-Kasem
SMSaul Martinez-Horta
Saul Martinez-Horta
JKJaime Kulisevsky
Jaime Kulisevsky

1 August 2021 in Journal of Clinical Neuroscience
Verified
Journal Article
Open access
JPJavier Pagonabarraga
Javier Pagonabarraga
MTMichele Tinazzi
Michele Tinazzi
CCCarla Caccia
Carla Caccia
Wolfgang JostWolfgang Jost
Wolfgang Jost
Glutamate is the major excitatory neurotransmitter in the central nervous system and, as such, many brain regions, including the basal ganglia, are rich in glutamatergic neurons. The importance of the basal ganglia in the control of voluntary movement has long been recognised, with the effect of dysfunction of the region exemplified by the motor symptoms seen in Parkinson's disease (PD). However, the basal ganglia and the associated glutamatergic system also play a role in the modulation of emotion, nociception and cognition, dysregulation of which result in some of the non-motor symptoms of PD (depression/anxiety, pain and cognitive deficits). Thus, while the treatment of PD has traditionally been approached from the perspective of dopaminergic replacement, using agents such as levodopa and dopamine receptor agonists, the glutamatergic system offers a novel treatment target for the disease. Safinamide has been approved in over 20 countries globally for fluctuating PD as add-on therapy to levodopa regimens for the management of 'off' episodes. The drug has both dopaminergic and non-dopaminergic pharmacological effects, the latter including inhibition of abnormal glutamate release. The effect of safinamide on the glutamatergic system might present some advantages over dopamine-based therapies for PD by providing efficacy for motor (levodopa-induced dyskinesia) as well as non-motor (anxiety, mood disorders, pain) symptoms. In this article, we discuss the potential role of glutamatergic inhibition on these symptoms, using illustrative real-world examples of patients we have treated with safinamide.

1 April 2019 in Human Brain Mapping
Verified
Journal Article
Closed access
PDF file
IAIgnacio Aracil‐Bolaños
Ignacio Aracil‐Bolaños
FSFrederic Sampedro
Frederic Sampedro
JMJuan Marín‐Lahoz
Juan Marín‐Lahoz
AHAndrea Horta‐Barba
Andrea Horta‐Barba
SMSaül Martínez‐Horta
Saül Martínez‐Horta
JPJavier Pagonabarraga
Javier Pagonabarraga